comparemela.com

Latest Breaking News On - New world medical - Page 2 : comparemela.com

Glaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: Analyst - Glaukos (NYSE:GKOS)

Needham expects Glaukos Corp (NYSE: GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside is expected from the accelerating iAccess and iPRIME launches.

A Class Act in Glaucoma Management: Differentiating Rho Kinase Inhibitors From the Pack

MIGS evolution augurs earlier intervention, stand-alone procedures

Ocular Surgery News | The volume of minimally invasive glaucoma surgery has increased significantly in recent years, providing an alternative to traditional glaucoma surgeries.Data from various studies demonstrate that MIGS is associated with low risk for adverse events and has beneficial effects on visual field preservation, quality of life and cost-effectiveness among patients with mild to moderate glaucoma.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.